跳至主要内容
临床试验/NCT04133623
NCT04133623已完成3 期

Ibuprofen Versus Ketorolac by Mouth in the Treatment of Acute Pain From Osteoarticular Trauma: a Randomized Double-blind Controlled Study.

IRCCS Burlo Garofolo3 个研究点 分布在 1 个国家目标入组 212 人开始时间: 2019年11月19日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
212
试验地点
3
主要终点
Pain reduction assessed on the NRS scale 60 minutes after the administration of the drug

研究概览

简要总结

Pain is the leading cause of access to the paediatric emergency department (ED) and present in up to 78% of cases.

Acute osteoarticular traumatic pain is often treated inadequately, and there is little data about the best treatment for children. The ibuprofen and ketorolac are respectively the most used and one of the most powerful NSAIDs. In literature, there is no direct comparison between those two medications.

The objective of the study depends on the level of pain:

  • in severe traumatic acute pain (>=7 points): to evaluate if ketorolac is superior to ibuprofen in the treatment of pain (n=130 children, 65 allocated to ketorolac and 65 to ibuprofen)
  • in moderate traumatic acute pain (<7 points): to evaluate if ibuprofen is not inferior to ketorolac in the treatment of pain (n=120 children, 60 allocated to ketorolac and 60 to ibuprofen)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

盲法说明

double dummy

入排标准

年龄范围
8 Years 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Age between 8 and 18 years
  • Moderate to severe pain (value>= 4 on the Numerical Rating scale / NRS)
  • Pain due to a trauma at limbs that has occurred in the last 48 hours

排除标准

  • Administration of any analgesic in the previous 8 hours.
  • Allergy known to one of the active ingredients
  • Known hepatopathy or nephropathy
  • Suspicion of violence by others
  • Chronic use of painkillers
  • Inability to report pain due to the presence of: intellectual disability (IQ <70); moderate-severe hearing loss; communication limitations such as patient mutism; unable to write; inability to speak Italian
  • Chronic neurological or metabolic diseases,
  • Positive history for ease of bleeding, coagulation disorder or
  • thrombocytopenia
  • A history of gastritis or esophagitis in the last 30 days
  • Multiple trauma
  • Vascular-vascular deficit
  • State of pregnancy

研究组 & 干预措施

Ketorolac

Experimental

Administration of ketorolac 0.5 mg/kg up to 10 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ibuprofen.

干预措施: Ketorolac (Drug)

Ibuprofen

Active Comparator

Administration of ibuprofen 10 mg/kg up to 600 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ketorolac.

干预措施: Ibuprofen (Drug)

结局指标

主要结局

Pain reduction assessed on the NRS scale 60 minutes after the administration of the drug

时间窗: 60 minutes after the administration of the drug

NRS scale will be asked after 60 minutes from the administration of the drug. To evaluate the NRS scale the patient is asked to express how much pain he feels through a number ranging from 0 to 10 in which 10 is the maximum pain. This is one of the most used methods in pain assessment. The difference will be calculated from the baseline.

次要结局

  • Patients who obtain a reduction of NRS of more than 3 points after 120 minutes from the administration of the drug(120 minutes after the administration of the drug.)
  • Adverse effects in the two groups(within 120 minutes from the administration of the drug)
  • Emergency department outcome(within 120 minutes from the administration of the drug)
  • NRS 30 minutes after the administration of the drug(30 minutes after the administration of the drug)
  • Patients who obtain a value of NRS <4 after 30 minutes from the administration of the drug.(30 minutes after the administration of the drug)
  • Patients who obtain a value of NRS <4 after 60 minutes from the administration of the drug(60 minutes after the administration of the drug.)
  • Patients who obtain a value of NRS <4 after 90 minutes from the administration of the drug.(90 minutes after the administration of the drug)
  • Patients who obtain a value of NRS <4 after 120 minutes from the administration of the drug.(120 minutes after the administration of the drug.)
  • Patients who obtain a reduction of NRS of more than 3 points after 30 minutes from the administration of the drug.(NRS scale will be asked after 30 minutes from the administration of the drug.)
  • Patients who obtain a reduction of NRS of more than 3 points after 60 minutes from the administration of the drug.(60 minutes after the administration of the drug.)
  • Patients who obtain a reduction of NRS of more than 3 points after 90 minutes from the administration of the drug.(90 minutes after the administration of the drug.)
  • NRS at time 90 minutes after the administration of the drug(90 minutes after the administration of the drug)
  • NRS at time 120 minutes after the administration of the drug(120 minutes after the administration of the drug)

研究者

发起方
IRCCS Burlo Garofolo
申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验